【レポートの概要（一部）】
1 Table of Contents
1 Table of Contents 7
1.1 List of Tables 13
1.2 List of Figures 15
2 Introduction 18
2.1 Report Scope 18
2.2 Upcoming Related Reports 19
2.3 Recently Published Reports 19
3 US Private Equity and Venture Capital Industry Dynamics 21
3.1 Post-2008 Financial Market Crash: Volume of Capital Commitments to Private Equity Funds Show Signs of Recovery 21
3.1.1 Venture Capital Fundraising Trend in the US 22
3.2 Volume over Value: Decrease in the Average Value of Completed Private Equity Healthcare Deals between 2007 and 2013 24
3.3 Healthcare Reform and Cost Pressures in Europe and North America Shifts Deal Activity to the Asia-Pacific Region 25
3.4 Private Equity Deals by Therapy Area 28
3.4.1 Central Nervous System, Immunology, Infectious Disease, Metabolic Disorders, and Oncology Enjoying Significant Investment 28
3.5 Private Equity Buyouts of 2013 30
3.6 Venture Capital Investment Trend 31
3.7 Venture Capital Investment: Biotechnology Plays Second Fiddle to Software 34
3.8 Seed-Stage Financing Shows Downward Trend 37
3.9 Venture-Backed Exits in 2013 38
3.9.1 Significant Venture-Backed Biotechnology Acquisitions in 2013 40
3.9.2 Venture-Backed Mergers and Acquisition Witness Strong End to 2013 40
3.10 California, Massachusetts, and New York Lead the Pack in Venture Capital Investment for 2013 42
4 Equity Offerings 44
4.1 Equity Offerings in the Healthcare Sector 44
4.2 Venture-Backed Initial Public Offerings in 2013 45
4.3 Venture-Backed Emerging Biotech Initial Public Offerings in 2013 46
4.4 Liquidity Position Makes Emerging Biotechs an Attractive Prospect for Investors 47
4.5 Company Profiles and Initial Public Offer Details 49
4.5.1 Intrexon Corporation (Stock Symbol: XON) 49
4.5.2 Ophthotech Corporation (Stock Symbol: OPHT) 51
4.5.3 PTC Therapeutics (Stock Symbol: PTCT) 52
4.5.4 Portola Pharmaceuticals (Stock Symbol: PTLA) 54
4.5.5 Agios Pharmaceuticals (Stock Symbol: AGIO) 55
4.5.6 Chimerix (Stock Symbol: CMRX) 57
4.5.7 Bluebird Bio (Stock Symbol: BLUE) 58
4.5.8 Foundation Medicine (Stock Symbol: FMI) 59
4.5.9 OncoMed Pharmaceuticals (Stock Symbol: OMED) 60
4.5.10 Acceleron Pharma (Stock Symbol: XLRN) 62
4.5.11 Prosensa Therapeutics (Stock Symbol: RNA) 64
4.5.12 Epizyme (Stock Symbol: EPZM) 65
4.5.13 Onconova Therapeutics (Stock Symbol: ONTX) 66
4.5.14 Tetraphase Pharmaceuticals (Stock Symbol: TTPH) 68
4.5.15 Esperion Therapeutics (Stock Symbol: ESPR) 69
5 Private Equity Firms: Company Drill-Downs 71
5.1 Section Overview 71
5.2 TPG Capital 72
5.2.1 Overview and Portfolio Management 72
5.2.2 Historical Deals Trend 74
5.2.3 Healthcare-Related Deals in 2013 76
5.3 The Carlyle Group 76
5.3.1 Overview and Portfolio Management 76
5.3.2 Historical Deals Trend 78
5.3.3 Healthcare-Related Deals in 2013 79
5.4 The Blackstone Group 80
5.4.1 Overview and Portfolio Management 80
5.4.2 Historical Deals Trend 82
5.4.3 Healthcare-Related Deals in 2013 83
5.5 Kohlberg Kravis Roberts 83
5.5.1 Overview and Portfolio Management 83
5.5.2 Historical Deals Trend 86
5.5.3 Healthcare-Related Deals in 2013 88
5.6 Warburg Pincus 89
5.6.1 Overview and Portfolio Management 89
5.6.2 Historical Deals Trend 90
5.6.3 Healthcare-Related Deals in 2013 92
5.7 Goldman Sachs Principal Investment Area 93
5.7.1 Overview and Portfolio Management 93
5.7.2 Historical Deals Trend 93
5.8 Advent International Corporation 95
5.8.1 Overview and Portfolio Management 95
5.8.2 Historical Deals Trend 96
5.8.3 Healthcare-Related Deals in 2013 98
5.9 Apollo Global Management 99
5.9.1 Overview and Portfolio Management 99
5.9.2 Healthcare-Related Deals in 2013 99
5.10 Bain Capital 99
5.10.1 Overview and Portfolio Management 99
5.10.2 Historical Deals Trend 100
5.10.3 Healthcare-Related Deals in 2013 101
5.11 CVC Capital Partners 101
5.11.1 Overview and Portfolio Management 101
5.11.2 Historical Deals Trend 102
5.12 Oaktree Capital Management 103
5.12.1 Overview and Portfolio Management 103
5.12.2 Historical Deals Trend 104
5.13 Hellman & Friedman 105
5.13.1 Overview and Portfolio Management 105
5.13.2 Historical Deals Trend 106
6 Venture Capital Firms: Company Drill-Downs 108
6.1 Section Overview 108
6.2 New Enterprise Associates 109
6.2.1 Overview and Portfolio Management 109
6.2.2 Historical Deals Trend 112
6.2.3 Biotechnology Exits and Initial Public Offerings in 2013 114
6.3 OrbiMed Advisors 115
6.3.1 Overview and Portfolio Management 115
6.3.2 Historical Deals Trend 117
6.3.3 Biotechnology Exits and Initial Public Offerings in 2013 119
6.4 Canaan Partners 120
6.4.1 Overview and Portfolio Management 120
6.4.2 Historical Deals Trend 122
6.4.3 Biotechnology Exits and Initial Public Offerings in 2013 123
6.5 Versant Ventures 123
6.5.1 Overview and Portfolio Management 123
6.5.2 Historical Deals Trend 125
6.5.3 Biotechnology Exits and Initial Public Offerings in 2013 127
6.6 New Leaf Venture Partners 128
6.6.1 Overview and Portfolio Management 128
6.6.2 Historical Deals Trend 129
6.6.3 Biotechnology Exits and Initial Public Offerings in 2013 131
6.7 Third Rock Ventures 132
6.7.1 Overview and Portfolio Management 132
6.7.2 Historical Deals Trend 134
6.7.3 Biotechnology Exits and Initial Public Offerings in 2013 136
6.8 Domain Associates 137
6.8.1 Overview and Portfolio Management 137
6.8.2 Historical Deals Trend 139
6.8.3 Biotechnology Exits and Initial Public Offerings in 2013 141
6.9 Kleiner Perkins Caufield & Byers 142
6.9.1 Overview and Portfolio Management 142
6.9.2 Historical Deals Trend 144
6.9.3 Biotechnology Exits and Initial Public Offerings in 2013 146
6.10 Clarus Ventures 147
6.10.1 Overview and Portfolio Management 147
6.10.2 Historical Deals Trend 148
6.10.3 Biotechnology Exits and Initial Public Offerings in 2013 150
6.11 Flagship Ventures 151
6.11.1 Overview and Portfolio Management 151
6.11.2 Historical Deals Trend 153
6.11.3 Biotechnology Exits and Initial Public Offerings in 2013 155
6.12 Additional Venture Capital Firms with Significant Biotechnology Investments 156
6.12.1 Novo A/S 156
6.12.2 InterWest Partners 158
6.12.3 Essex Woodlands Health Ventures 160
6.12.4 Alta Partners 162
6.12.5 Third Security 164
7 Strategic Outlook 166
7.1 New Financing Models Needed for Sustainable Growth of Emerging Biotechs 166
7.2 Aggressive Growth Will Continue in the Asia-Pacific Region 167
7.3 Small and Midsize Funds Will Enjoy Significant Deal Activity 167
7.4 Initial Public Offering Activity Will Increase in 2014 168
7.5 Increased Pressure on Venture Capital Firms 168
8 Appendix 169
8.1 Bibliography 169
8.2 Abbreviations 174
8.3 Research Methodology 178
8.3.1 Coverage 178
8.3.2 Secondary Research 178
8.3.3 Expert Panel Validation 179
8.4 About the Authors 180
8.4.1 Analyst 180
8.4.2 Director of Healthcare Industry Dynamics 180
8.4.3 Global Head of Healthcare 181
8.5 About the Industry Dynamics Team 181
8.6 About GlobalData 182
8.7 Disclosure Information 182
8.8 Disclaimer 182
【レポート販売概要】
■ タイトル：バイオ技術投資レポート：プライベート・エクイティ及びベンチャーキャピタル投資動向■ 英文：PharmaSphere: Emerging Biotech Investment Report - Strategic Trends in Private Equity and Venture Capital Funding
■ 発行日：2014年3月12日
■ 調査会社：GlobalData
■ 商品コード：GDHC005PSR
■ 調査対象地域：グローバル
- 予測遺伝子検査と消費者/ウェルネスゲノミクスの世界市場分析：用途別（がん、糖尿病のスクリーニング、パーキンソン病、循環器、整形外科･筋骨格系、ヌートリア遺伝学、皮膚･代謝遺伝学）、動向分析、2013-2025The global predictive genetic testing & consumer/wellness genomics market is anticipated to reach USD 4.6 billion by 2025, according to a new report by Grand View Research, Inc. Key drivers attributing to the market expansion include rising awareness pertaining to the use of genomic tests for the prediction of gene susceptibility for probability of disease development. Genetic data in the ecosyste …
- 人感センサーの世界市場：PIRセンサー、超音波センサーAbout Occupancy Sensor Market The market is driven by the increased adoption of PIR sensors and ultrasonic sensors in the residential and commercial sector. Erosion in the prices of PIR sensors has led to their increased adoption in automotive production, video surveillance, military applications, and medical use. The use of occupancy sensors in private offices, classrooms, closets, hallways, corr …
- 世界のビタミンD検査市場動向（2014-2018）TechNavio's analysts forecast the Global Vitamin D Testing Market to grow at a CAGR of 32.36 percent over the period 2013-2018. One of the key factors contributing to this market growth is the increase in aging and chronically ill populations worldwide. The Global Vitamin D Testing Market has also been witnessing the increase in product approvals. However, the stringent regulatory requirements cou …
- 電子用接着剤の世界市場2017-2021：導電性接着剤、熱伝導性接着剤、UV硬化接着剤About Electronic Adhesives Electronic adhesives are used for making interconnections between wires or other electronic components on a printed circuit board (PCB). They are extensively used in the manufacture and assembly of electronic circuits and products. These adhesives are used in the assembly and packaging of the electronic devices. The electronics market caters to various industries includi …
- スマートガスメーターの世界市場：AMR、AMIThe smart gas meter market is projected to grow at a CAGR of 7.24% from 2016 to 2021 to reach USD 2.27 Billion by 2021. Government policies & mandates in developed economies and accurate billing & improved customer service are the major factors driving the market. The report segments the smart gas meter market on the basis of end-user into residential, commercial, and industrial. Residential custo …
- Norwegian Energy Company ASA：石油・ガスの開発・生産動向及びコスト分析- Q3, 2013Norwegian Energy Company ASA Oil & Gas Exploration and Production Operations and Cost Analysis - Q3, 2013 Summary Norwegian Energy Company ASA Oil & Gas Exploration and Production Operations and Cost Analysis is the latest report from GlobalData, the industry analysis specialists, that offers comprehensive information on the operational and financial performance of the company. The report is an es …
- 空港小売サーベイおよびラグジュアリー動向Summary “Airport Retail Survey and Luxury Trends 2015-2016” is a new report by Conlumino that globally analyzes prevailing trends in airport retailing and explores how travelers use airport retailing with specific insight on luxury brands, and how the dynamics are set to change in 2015-2016. This report highlights the key factors influencing customer opinion and purchasing patterns, and identifies …
- 子宮内膜症治療薬の世界市場予測・研究開発動向Endometriosis Medicines – Your 2016 Guide to Sales Potentials of that Rising, Underserved Female Health Market What does the future hold for treating endometriosis, a common disease? Our new analysis forecasts sales of drugs treating that menstrual cycle disorder. Visiongain’s report gives predictions to 2026 at overall world market, product and national level. Avoid falling behind in data or losi …
- レジオネラ検査の世界市場規模・予測：用途別（水試験[微生物培養、DFA染色、PCR、その他]、IVD検査[血液培養、尿中抗原検査、DFA染色、PCR、その他]）、地域別、動向分析、2013-2025The global legionella testing market is expected to reach USD 352.6 million by 2025, according to a new study by Grand View Research Inc. The increasing prevalence of Legionella-related disorders, along with requirements of rapid diagnostic procedures, is expected to drive the industry growth. According to CDC, the number of people suffering from Legionnaires’ disease was 4,548 in 2013. The incide …
- クロスプラットフォーム及びモバイル広告の世界市場予測The consumer attention has shifted from traditional media channels to always on screens; these consumers are combining multiple devices in new way for multi-task to amplify their experience, share the content, and connect with others. Consumers’ interaction on these devices reveals their behavior, need, interest for shopping. Based on these information marketers can reach their customers through r …
- 医療産業向けBPO（ビジネスプロセスアウトソーシング）の世界市場予測（～2021）The healthcare BPO market is projected to reach USD 276.79 Billion by 2021 from USD 170.47 Billion in 2016, growing at a CAGR of 10.2% during the forecast period (2016–2021). The pressure to reduce healthcare delivery costs, consolidation of healthcare systems, enactment of PPACA, stringent regulatory requirements, and complex clinical trial protocols are the major drivers for the healthcare BPO m …
- Hugoton Royalty Trust：石油・ガスの開発・生産動向及びコスト分析– Q4, 2012Hugoton Royalty Trust Oil & Gas Exploration and Production Operations and Cost Analysis – Q4, 2012 Summary Hugoton Royalty Trust Oil & Gas Exploration and Production Operations and Cost Analysis is the latest report from GlobalData, the industry analysis specialists, that offers comprehensive information on the operational and financial performance of the company. The report is an essential source …
- ヒトパピローマウイルス（HPV）治療薬の世界市場2019-2023About this market Technological advances in diagnostics to drive market growth. The diagnostic methods that are currently available in the market include Pap test, colposcopy, and HPV DNA test. Pap test is a screening procedure for cervical cancer, in which the presence of precancerous or cancerous cells is identified on the cervix. Colposcopy is a more advanced technique like a Pap test, which al …
- 澱粉誘導体の世界市場：マルトデキストリン、シクロデキストリン、グルコースシロップ、噴霧乾燥澱粉、加水分解物This report analyzes the starch derivatives market, in terms of region, function, type, and application. The starch derivatives market has grown exponentially in the last few years and this trend is projected to continue following the same trend until 2020. The market was valued at USD 45.74 million in 2014 and is projected to grow at a CAGR of 6.1% from 2015 to 2020. In terms of volume, the marke …
- 射出成型機の世界市場2016-2020：自動車、消費財、包装、家電、ITAbout Injection Molding Machine Injection molding is the most commonly used manufacturing process for the fabrication of plastic parts. Injection molding is used to manufacture a wide variety of products, which vary considerably in their dimensions, complex structures, and end-use applications. The injection molding is done by an injection molding machine and requires plastic and the typical raw m …
